• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease.

作者信息

Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A

机构信息

Institute of Neurology, University of Bologna, Italy.

出版信息

Neurology. 1994 Jul;44(7):1287-92. doi: 10.1212/wnl.44.7.1287.

DOI:10.1212/wnl.44.7.1287
PMID:8035932
Abstract

We prospectively evaluated over 4 years the intrasubject relationship between levodopa plasma concentration and the tapping effect after a standard oral levodopa test in 28 patients with mild-to-moderate idiopathic Parkinson's disease. The onset and duration of the tapping effect significantly shortened over years; response amplitude did not vary. Levodopa plasma kinetics remained unchanged. Pharmacodynamic modeling indicated a progressive decrease in the equilibration half-life between plasma drug concentration and effect, which correlated with the shorter motor response. No clear-cut change in maximum response (Emax) emerged, but levodopa concentration needed to yield 50% of maximum effect (EC50) significantly increased. These data indicate that the duration of motor response becomes a major determinant of drug efficacy over years. The modifications in levodopa effect-compartment equilibration half-life and EC50 further support the suggestion that alterations in cerebral levodopa kinetics have an important role in the development of response fluctuations.

摘要

相似文献

1
Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease.
Neurology. 1994 Jul;44(7):1287-92. doi: 10.1212/wnl.44.7.1287.
2
Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease.口服左旋多巴的药效学建模:在帕金森病中的临床应用
Neurology. 1993 Feb;43(2):367-71. doi: 10.1212/wnl.43.2.367.
3
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.模拟帕金森病对外源性左旋多巴和内源性左旋多巴产生的短期和长期反应。
J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):243-68. doi: 10.1023/b:jopa.0000039566.75368.59.
4
Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.左旋多巴与阿扑吗啡联用对出现剂末运动波动的帕金森病患者的药效学研究
Clin Neuropharmacol. 1998 Mar-Apr;21(2):86-92.
5
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.帕金森病中左旋多巴的药代动力学机制与运动波动
Ann Neurol. 1987 Apr;21(4):370-6. doi: 10.1002/ana.410210409.
6
Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach.帕金森病患者左旋多巴治疗监测:一种动力学-动态学方法。
Ther Drug Monit. 2001 Dec;23(6):621-9. doi: 10.1097/00007691-200112000-00005.
7
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.帕金森病的运动波动:中枢病理生理机制,第二部分。
Ann Neurol. 1988 Sep;24(3):372-8. doi: 10.1002/ana.410240304.
8
Concentration-effect relationship of levodopa in patients with Parkinson's disease.帕金森病患者左旋多巴的浓度-效应关系。
Clin Pharmacokinet. 1995 Oct;29(4):243-56. doi: 10.2165/00003088-199529040-00004.
9
No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.慢性溴隐亭治疗对帕金森病患者左旋多巴药代动力学无影响。
Clin Neuropharmacol. 1992 Dec;15(6):505-8. doi: 10.1097/00002826-199212000-00008.
10
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.脉冲式左旋多巴给药对中枢多巴胺药效学的急性影响。
Neurology. 1991 May;41(5):630-3. doi: 10.1212/wnl.41.5.630.

引用本文的文献

1
Understanding the progression of Parkinson's disease: a review.了解帕金森病的进展:综述
BMJ Neurol Open. 2025 Sep 8;7(2):e001215. doi: 10.1136/bmjno-2025-001215. eCollection 2025.
2
Biochemical Sensors for Personalized Therapy in Parkinson's Disease: Where We Stand.用于帕金森病个性化治疗的生化传感器:我们的现状
J Clin Med. 2024 Dec 7;13(23):7458. doi: 10.3390/jcm13237458.
3
Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.
帕金森病中的左旋多巴诱发异动症:病理生理学、临床表现、治疗管理策略及未来方向概述
J Clin Med. 2023 Jun 30;12(13):4427. doi: 10.3390/jcm12134427.
4
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease.限制还是不限制?优化饮食中蛋白质对帕金森病左旋多巴吸收的相互作用的实际考量。
NPJ Parkinsons Dis. 2023 Jun 24;9(1):98. doi: 10.1038/s41531-023-00541-w.
5
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.性别是左旋多巴临床药代动力学的主要决定因素:来自左旋多巴治疗药物监测的大量系列证据。
J Parkinsons Dis. 2022;12(8):2519-2530. doi: 10.3233/JPD-223374.
6
Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.定量评估低亚急性左旋多巴剂量对发病时帕金森病的运动反应:BoProPark 队列研究数据。
J Parkinsons Dis. 2021;11(2):811-819. doi: 10.3233/JPD-202262.
7
Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease.多巴胺缓冲能力成像:一种用于帕金森病分期的药效功能磁共振成像方法。
Front Neurol. 2020 May 6;11:370. doi: 10.3389/fneur.2020.00370. eCollection 2020.
8
Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease.帕金森病患者左旋多巴运动反应的数学建模和参数估计。
PLoS One. 2020 Mar 3;15(3):e0229729. doi: 10.1371/journal.pone.0229729. eCollection 2020.
9
Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.急性左旋多巴治疗对初发帕金森病患者的功能性脑网络影响较小。
Mov Disord. 2020 Mar;35(3):499-503. doi: 10.1002/mds.27942. Epub 2019 Dec 19.
10
Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.用于通过血脑屏障进行药物递送的麦芽糊精修饰脂质体。
Medchemcomm. 2017 May 5;8(6):1337-1345. doi: 10.1039/c7md00045f. eCollection 2017 Jun 1.